KTTA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2023Q4

FY2024Q1

-3.800

-0.37%

-0.180

-92.71%

Estimates Revision

The market is revising No Change the revenue expectations for Pasithea Therapeutics Corp. (KTTA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 57.22%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+57.22%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Pasithea Therapeutics Corp (KTTA.O) is -1.32, compared to its 5-year average forward P/E of -4.52. For a more detailed relative valuation and DCF analysis to assess Pasithea Therapeutics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.52

Current PE

-1.32

Overvalued PE

5.78

Undervalued PE

-14.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.70

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

6.58

Undervalued EV/EBITDA

-7.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.54

Current PS

0.00

Overvalued PS

52.51

Undervalued PS

-31.43

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KTTA News & Events

Events Timeline

No data

News

8.5

12-02Newsfilter

Pasithea Therapeutics Closes $60M Public Offering of 80M Shares

2.0

12-01Benzinga

Vision Marine Technologies Stock Rises Over 10%; Check Out 20 Stocks Making Moves in Premarket Trading

8.5

12-01NASDAQ.COM

Pasithea Announces $60 Million Offering to Support PAS-004 and Expand Pipeline

People Also Watch

Frequently Asked Questions

What is Pasithea Therapeutics Corp (KTTA) stock price today?

The current price of KTTA is 1.17 USD — it has increased 0.86 % in the last trading day.

What is Pasithea Therapeutics Corp (KTTA)'s business?

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

What is the price predicton of KTTA Stock?

Wall Street analysts forecast KTTA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KTTA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Pasithea Therapeutics Corp (KTTA)'s revenue for the last quarter?

Pasithea Therapeutics Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Pasithea Therapeutics Corp (KTTA)'s earnings per share (EPS) for the last quarter?

Pasithea Therapeutics Corp. EPS for the last quarter amounts to -0.41 USD, decreased -85.71 % YoY.

What changes have occurred in the market's expectations for Pasithea Therapeutics Corp (KTTA)'s fundamentals?

How many employees does Pasithea Therapeutics Corp (KTTA). have?

Pasithea Therapeutics Corp (KTTA) has 4 emplpoyees as of December 16 2025.

What is Pasithea Therapeutics Corp (KTTA) market cap?

Today KTTA has the market capitalization of 25.98M USD.